SG11202106481SA - Controlled fucosylation of antibodies - Google Patents
Controlled fucosylation of antibodiesInfo
- Publication number
- SG11202106481SA SG11202106481SA SG11202106481SA SG11202106481SA SG11202106481SA SG 11202106481S A SG11202106481S A SG 11202106481SA SG 11202106481S A SG11202106481S A SG 11202106481SA SG 11202106481S A SG11202106481S A SG 11202106481SA SG 11202106481S A SG11202106481S A SG 11202106481SA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- fucosylation
- controlled
- controlled fucosylation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781691P | 2018-12-19 | 2018-12-19 | |
| PCT/US2019/067222 WO2020132096A1 (en) | 2018-12-19 | 2019-12-18 | Controlled fucosylation of antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106481SA true SG11202106481SA (en) | 2021-07-29 |
Family
ID=71100565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106481SA SG11202106481SA (en) | 2018-12-19 | 2019-12-18 | Controlled fucosylation of antibodies |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220081477A1 (en) |
| EP (1) | EP3897664A4 (en) |
| JP (1) | JP2022514299A (en) |
| KR (1) | KR20210104837A (en) |
| CN (1) | CN113438951A (en) |
| AU (1) | AU2019402923A1 (en) |
| CA (1) | CA3123591A1 (en) |
| IL (1) | IL284086A (en) |
| MX (1) | MX2021007327A (en) |
| SG (1) | SG11202106481SA (en) |
| WO (1) | WO2020132096A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3197930A1 (en) * | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013201195A1 (en) * | 2006-10-24 | 2013-03-21 | Emergent Product Development Seattle, Llc | A method for increasing antibody-dependent cytotoxicity with castanospermine |
| CA2723197C (en) * | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| SG10201913099YA (en) * | 2014-10-29 | 2020-02-27 | Seattle Genetics Inc | Dosage and administration of non-fucosylated anti-cd40 antibodies |
| KR20180086233A (en) * | 2015-12-04 | 2018-07-30 | 시애틀 지네틱스, 인크. | Cancer treatments using 2-deoxy-2-fluoro-L-fucose in combination with checkpoint inhibitors |
| MX2018008447A (en) * | 2016-01-06 | 2019-05-30 | Oncobiologics Inc | Modulation of afucosylated species in a monoclonal antibody composition. |
| IL260732B1 (en) * | 2016-02-17 | 2024-04-01 | Seagen Inc | Bcma antibodies and use of same to treat cancer and immunological disorders |
| EP3257866A1 (en) * | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modified anti-tnf antibody and use thereof in the treatment of ibd |
-
2019
- 2019-12-18 SG SG11202106481SA patent/SG11202106481SA/en unknown
- 2019-12-18 CA CA3123591A patent/CA3123591A1/en active Pending
- 2019-12-18 WO PCT/US2019/067222 patent/WO2020132096A1/en unknown
- 2019-12-18 AU AU2019402923A patent/AU2019402923A1/en active Pending
- 2019-12-18 JP JP2021534983A patent/JP2022514299A/en active Pending
- 2019-12-18 US US17/309,778 patent/US20220081477A1/en active Pending
- 2019-12-18 MX MX2021007327A patent/MX2021007327A/en unknown
- 2019-12-18 EP EP19899492.3A patent/EP3897664A4/en active Pending
- 2019-12-18 CN CN201980092085.1A patent/CN113438951A/en active Pending
- 2019-12-18 KR KR1020217022526A patent/KR20210104837A/en unknown
-
2021
- 2021-06-16 IL IL284086A patent/IL284086A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL284086A (en) | 2021-08-31 |
| JP2022514299A (en) | 2022-02-10 |
| WO2020132096A1 (en) | 2020-06-25 |
| EP3897664A1 (en) | 2021-10-27 |
| MX2021007327A (en) | 2021-09-08 |
| KR20210104837A (en) | 2021-08-25 |
| CN113438951A (en) | 2021-09-24 |
| US20220081477A1 (en) | 2022-03-17 |
| AU2019402923A1 (en) | 2021-07-15 |
| CA3123591A1 (en) | 2020-06-25 |
| EP3897664A4 (en) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280780A (en) | Anti-tigit antibodies | |
| EP3387442A4 (en) | Humanized anti-cd73 antibodies | |
| IL279352A (en) | Il-11ra antibodies | |
| IL280013A (en) | Anti-il36r antibodies | |
| IL278010A (en) | Galectin-10 antibodies | |
| EP3380524A4 (en) | Humanized anti-cll-1 antibodies | |
| IL282668A (en) | Humanized antibodies against c-kit | |
| IL268731A (en) | New uses of anti-sirpg antibodies | |
| IL282756A (en) | Humanized anti-sirpα antibodies | |
| IL281738A (en) | Trem2 stabilizing antibodies | |
| IL277030A (en) | Antibodies | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| SG11202007735TA (en) | Anti-her2 antibodies | |
| EP3893931A4 (en) | Methods of using anti-trem2 antibodies | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| GB201806072D0 (en) | Methods of manufacture | |
| EP3894768C0 (en) | Methods of cryo-curing | |
| EP3867272A4 (en) | Use of anti-fam19a5 antibodies | |
| GB201806084D0 (en) | Antibodies | |
| GB201805904D0 (en) | Methods of Manufacture | |
| GB201704115D0 (en) | Method of selecting for antibodies | |
| EP3365367A4 (en) | Anti-bed bug monoclonal antibodies and methods of making and uses thereof | |
| IL284086A (en) | Controlled fucosylation of antibodies | |
| IL269419A (en) | Treatment of lupus using humanized anti-cxcr5 antibodies |